MDC
Director Trades
| Date | Director | Value |
|---|
Company News
Medlab Clinical’s NanaBis drug dramatically improves cancer bone pain for first patient group in treatment study
Australian biotech Medlab Clinical (ASX: MDC) has reported the first cohort of patients undergoing a 12-month study of its NanaBis cannabinoid treatment for cancer-induced bone pain have registered a dramatic improvement in their pain scores. An interim analysis of 119 patients who have completed six and 12-month administration of the drug has showed a 55% reduction in […]
Medlab Clinical to be granted European patent for NanoCelle drug delivery platform
Australian biotech Medlab Clinical (ASX: MDC) has announced it has received notice from the European Patent Office of its intention to grant a patent covering the use of the company’s NanoCelle drug delivery platform. The patent, filed in 2016 and titled Transmucosal and transdermal delivery systems, will provide protection for the NanoCelle sub-micron delivery system […]
Medlab Clinical tops up cash reserves, builds board capabilities with new appointment
Medlab Clinical (ASX: MDC) has topped up its cash reserves with a $15 million placement, while boosting its board expertise with the appointment of “leading” pharmaceutical executive Cheryl Maley. The company announced on Friday it had raised $15 million (before costs) via a two-tranche placement of 62.5 million shares at $0.24 each to sophisticated and […]
Medlab Clinical heads into H2 2021 with strong momentum following ‘very pleasing’ H1
Biotech Medlab Clinical (ASX: MDC) has ended the H1 of the 2021 financial year with $6.8 million cash in the bank with increasing early revenue from Special Access Scheme (SAS) sales of its NanaBis and NanoCBD products along with ongoing nutraceutical sales. During the period, Medlab’s revenue from ordinary operations rose 77.4% to $4.5 million […]
Medlab Clinical partners with Arrotex to accelerate NanoCBD availability in Australian pharmacies
Medlab Clinical (ASX: MDC) has collared a heads of agreement with Australia’s largest generic over-the-counter (OTC) supplier Arrotex to fast-track availability of its proprietary cannabinoid formulation NanoCBD throughout Australian pharmacies. The deal’s intent is to accelerate the clinical package required for final lodgement and securing Therapeutic Goods Administration approval as a Scheduled 3 or pharmacist […]
Medlab Clinical’s probiotic NRGBiotic found to assist in reducing depression symptoms
Preliminary analysis of a phase IIa trial using Medlab Clinical’s (ASX: MDC) probiotic NRGBiotic has revealed a “significant” reduction in depression. The trial involved administering NRGBiotic to patients diagnosed with major depression. The probiotic was given in combination with a patient’s anti-depressant prescription which was either a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor. […]
Medlab Clinical to confirm NanaBis’ potential as non-opioid pain treatment in phase three trials
Australian biotech Medlab Clinical (ASX: MDC) could be the world’s first drug developer to have a registered cannabis-based medicine that outperforms opioids for cancer-related pain management, should its upcoming phase three trials be successful. The company aims to develop therapeutic pathways for diagnosed chronic diseases including pain, depression. Its most advanced drug candidate, NanaBis™, is […]
Medlab Clinical collars US FDA IND approval for cancer-pain treatment NanaBis
Medlab Clinical (ASX: MDC) has collared clinical investigational new drug status from the United States Food and Drug Administration for its lead candidate NanaBis, which is designed for treating cancer-related pain. IND status from the FDA paves the way for the cannabis-based NanaBis formulation to be used in a phase III trial in the US […]
Drawbacks of the TGA’s cannabis changes for listed pot stocks
Having been subject to a harsh reality check over the last year or so, the ASX-listed cannabis sector is applauding the local medicine regulator’s endorsement of the weed as an effective therapy that should be more freely available to the ailing masses. But the path to the pharmacy is likely to be harder than they […]
Medlab’s NanaBis spray deemed safe for chronic pain management in patients with advanced breast and prostate cancers
Results from an advanced cancer pain clinical trial using NanaBis oro-buccal spray developed by Medlab Clinical (ASX: MDC) has found the novel drug candidate to be safe, tolerable and fast-acting with mild adverse effects. The trial at Sydney’s Royal North Shore Hospital was a Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) investigation into […]
